Cargando…

ICER’s Version of HTA Is Positioned to Guide U.S. Health Care Reform

Detalles Bibliográficos
Autor principal:	Watkins, John B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10391149/ https://www.ncbi.nlm.nih.gov/pubmed/32857657 http://dx.doi.org/10.18553/jmcp.2020.26.9.1171

Ejemplares similares

Worldwide HTA access to ICER's cost-effectiveness models
Publicado: (2020)

HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales
por: Thokala, Praveen, et al.
Publicado: (2020)

Should Drug Companies Engage with ICER? An Empirical Analysis of How Often Manufacturers Engage with ICER and Whether Engagement May Influence ICER’s Cost-Effectiveness Estimates
por: Breslau, Rachel Milstein, et al.
Publicado: (2022)

HTA and economics in the United States: a systematic review of ICER reports to evaluate trends, identify factors associated with recommendations, and understand implications
por: Kruzikas, Denise T, et al.
Publicado: (2020)

Republican Rules of Reproduction and “Flipping the Script” on U.S. Health Care Reform
por: Loeppky, Rodney
Publicado: (2023)

Evidence for tuning adipocytes ICER levels for obesity care
por: Brajkovic, Saška, et al.
Publicado: (2012)

A field guide to U.S. healthcare reform: The evolution to value‐based healthcare
por: Harrill, Willard C., et al.
Publicado: (2021)

ICER is requisite for Th17 differentiation
por: Yoshida, Nobuya, et al.
Publicado: (2016)

The ICER review is in: hope amidst uncertainty
por: Begolka, Wendy Smith, et al.
Publicado: (2022)

Health care reforms
por: Marušič, Dorjan, et al.
Publicado: (2016)

The evolution of ICER’s review process for new medical interventions and a critical review of economic evaluations (2018-2019): how stakeholders can collaborate with ICER to improve the quality of evidence in ICER’s reports
por: Ronquest, Naoko A, et al.
Publicado: (2021)

The initial effect of U.S. tax reform on foreign acquisitions
por: Amberger, Harald J., et al.
Publicado: (2023)

A layman's guide to the U.S. health care system
por: De Lew, Nancy, et al.
Publicado: (1992)

Transportation: De-icers Add Sweet to Salt
por: Tenenbaum, David
Publicado: (2008)

ICER, ISPOR AND QALYs: Tales of Imaginary Worlds
por: Langley, Paul C
Publicado: (2019)

CVS Health and the Imaginary Worlds of the Institute for Clinical and Economic Review (ICER)
por: Langley, Paul C
Publicado: (2018)

ICER update to pricing models of remdesivir for COVID-19
Publicado: (2020)

ICER's timelines for assessments extended due to COVID-19
Publicado: (2020)

ICER’s assessment of lasmiditan, rimegepant, and ubrogepant for acute migraine
por: Franklin, Meg, et al.
Publicado: (2020)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Health Care Reform Simplified: Guide Your Family And Your Business Through Health Care Reform
por: Parks, Dave
Publicado: (2011)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

ICER releases pricing models for potential COVID-19 treatments
Publicado: (2020)

ICER's second update to pricing models of remdesivir for COVID-19
Publicado: (2020)

Inducible cAMP Early Repressor (ICER) and Brain Functions
por: Borlikova, Gilyana, et al.
Publicado: (2009)

ICER publishes draft scoping report on COVID-19 treatments
Publicado: (2021)

Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma
por: Langley, Paul C
Publicado: (2022)

U.S. sperm trend conclusions.
por: James, W H
Publicado: (1999)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

Ethical analysis in HTA of complex health interventions
por: Lysdahl, Kristin Bakke, et al.
Publicado: (2016)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

ICER releases evidence report on elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2020)

Value Assessment in Cystic Fibrosis: ICER’s Rejection of the Axioms of Fundamental Measurement
por: Langley, Paul C
Publicado: (2020)

ICER report on Alzheimer’s disease: implications from a patient perspective
por: Franklin, Meg
Publicado: (2021)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Evaluating a Stone of Hope: ICER’s 2019 Review of Treatments for Duchenne Muscular Dystrophy
por: Brandsema, John Frederick
Publicado: (2020)

Health care reform in the US: an analysis of implementation of the Affordable Care Act in California
por: Roby, Dylan, et al.
Publicado: (2014)

PDE8 Regulates Rapid Teff Cell Adhesion and Proliferation Independent of ICER
por: Vang, Amanda G., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_3fglvojpsu7nus8ueqp0f0gm7p